CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, delivered a presentation titled “The History and Promise of anti-CD154 Monoclonal Antibody Immunomodulation for Transplantation,” at the 61st Annual Congress of the Japan Society for Tra ...

Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on pain management therapies and vaccines for public health challenges [3] - The company has a development portfolio primarily targeting central nervous system (CNS) disorders [3] Key Product Candidates - TNX-102 SL is a product candidate for fibromyalgia management, with an NDA submitted based on two statistically significant Phase 3 studies, and a PDUFA goal date of August 15, 2025 [3] - TNX-102 SL has received Fast Track designation from the FDA for fibromyalgia management [3] - The company is also developing TNX-102 SL for acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina [3] Immunology and Infectious Disease Portfolio - Tonix's immunology portfolio includes TNX-1500, an Fc-modified humanized monoclonal antibody targeting CD40-ligand for preventing allograft rejection and treating autoimmune diseases [3] - The infectious disease portfolio features TNX-801, a vaccine for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent with a contract worth up to $34 million over five years with the U.S. Department of Defense [3] Commercial Products - Tonix Medicines, the commercial subsidiary, markets Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) for treating acute migraine in adults [3]